197 related articles for article (PubMed ID: 1708033)
1. Smoking, antihypertensive treatment benefit, and comprehensive antihypertensive treatment approach: some thoughts on the results of the International Prospective Primary Prevention Study in Hypertension.
Bolli P; Bühler FR; McKenzie JK
J Cardiovasc Pharmacol; 1990; 16 Suppl 7():S77-80. PubMed ID: 1708033
[TBL] [Abstract][Full Text] [Related]
2. Primary prevention with beta-blockade in patients with hypertension: review of results and clinical implications.
Wikstrand J
J Cardiovasc Pharmacol; 1990; 16 Suppl 5():S64-75. PubMed ID: 11527139
[TBL] [Abstract][Full Text] [Related]
3. Beta-blockers and primary cardioprotection in hypertension.
Fogari R; Zoppi A
Drugs Exp Clin Res; 1990; 16(3):113-22. PubMed ID: 1974838
[TBL] [Abstract][Full Text] [Related]
4. [Do beta-blockers prevent coronary events in hypertensive patients?].
Diévart F; Ragot S; Julien J; Herpin D
Arch Mal Coeur Vaiss; 2005 Sep; 98(9):881-8. PubMed ID: 16231574
[TBL] [Abstract][Full Text] [Related]
5. Antihypertensive therapy and myocardial infarction: focus on calcium antagonists.
Bühler FR; Müller FB; Linder L; Bolli P
J Hypertens Suppl; 1985 Nov; 3(2):S95-8. PubMed ID: 2868083
[TBL] [Abstract][Full Text] [Related]
6. [Retrospective studies and prospects of therapy for hypertension].
Maisch B; Brilla C; Kruse T; Noll B; Bethge C
Herz; 1995 Dec; 20(6):370-89. PubMed ID: 8582697
[TBL] [Abstract][Full Text] [Related]
7. Coronary artery disease can be prevented by antihypertensive therapy: experiences from the MAPHY Study.
Tuomilehto J; Wikstrand J; Warnold I; Olsson G; Elmfeldt D; Berglund G
J Cardiovasc Pharmacol; 1990; 16 Suppl 7():S75-6. PubMed ID: 1708032
[TBL] [Abstract][Full Text] [Related]
8. The Hypertension Optimal Treatment study and the importance of lowering blood pressure.
Hansson L
J Hypertens Suppl; 1999 Feb; 17(1):S9-13. PubMed ID: 10340838
[TBL] [Abstract][Full Text] [Related]
9. A 26-week, prospective, open-label, uncontrolled, multicenter study to evaluate the effect of an escalating-dose regimen of trandolapril on change in blood pressure in treatment-naive and concurrently treated adult hypertensive subjects (TRAIL).
Tytus RH; Burgess ED; Assouline L; Vanjaka A
Clin Ther; 2007 Feb; 29(2):305-15. PubMed ID: 17472822
[TBL] [Abstract][Full Text] [Related]
10. The future of antihypertensive treatment.
Israili ZH; Hernández-Hernández R; Valasco M
Am J Ther; 2007; 14(2):121-34. PubMed ID: 17414579
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular events in elderly patients with isolated systolic hypertension. A subgroup analysis of treatment strategies in STOP-Hypertension-2.
Ekbom T; Linjer E; Hedner T; Lanke J; De Faire U; Wester PO; Dahlöf B; Scherstén B
Blood Press; 2004; 13(3):137-41. PubMed ID: 15223721
[TBL] [Abstract][Full Text] [Related]
12. Discordant beta-blocker effects on clinic, ambulatory, resting, and exercise hemodynamics in patients with hypertension.
Beitelshees AL; Zineh I; Yarandi HN; Pauly DF; Johnson JA
Pharmacotherapy; 2006 Sep; 26(9):1247-54. PubMed ID: 16945046
[TBL] [Abstract][Full Text] [Related]
13. Aims of treatment of hypertension.
Hansson L
J Cardiovasc Pharmacol; 1987; 10 Suppl 2():S51-4; discussion S55. PubMed ID: 2481170
[TBL] [Abstract][Full Text] [Related]
14. [Stress-associated hypertension in the work place: results of the STARLET project].
Lüders S; Hammersen F; Kulschewski A; Frerichs A; Frieg R; Hahnheiser D; Reich G; Schnieders M; Schrandt G; Schrader J
Dtsch Med Wochenschr; 2006 Nov; 131(46):2580-5. PubMed ID: 17096303
[TBL] [Abstract][Full Text] [Related]
15. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B
Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679
[TBL] [Abstract][Full Text] [Related]
16. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs.
Adigun AQ; Ishola DA; Akintomide AO; Ajayi AA
J Hum Hypertens; 2003 Apr; 17(4):277-85. PubMed ID: 12714973
[TBL] [Abstract][Full Text] [Related]
17. [Hypertension management in general practice in Iceland].
Jensdóttir JO; Sigurethsson EL; Thornorgeirsson G
Laeknabladid; 2006 May; 92(5):375-80. PubMed ID: 16741320
[TBL] [Abstract][Full Text] [Related]
18. Low mortality from all causes, including myocardial infarction, in well-controlled hypertensives treated with a beta-blocker plus other antihypertensives.
Cruickshank JM; Pennert K; Sörman AE; Thorp JM; Zacharias FM; Zacharias FJ
J Hypertens; 1987 Aug; 5(4):489-98. PubMed ID: 3668249
[TBL] [Abstract][Full Text] [Related]
19. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.
Dahlöf B; Devereux R; de Faire U; Fyhrquist F; Hedner T; Ibsen H; Julius S; Kjeldsen S; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H
Am J Hypertens; 1997 Jul; 10(7 Pt 1):705-13. PubMed ID: 9234823
[TBL] [Abstract][Full Text] [Related]
20. Beta-blockade in the primary prevention of coronary heart disease in hypertensive patients. Review of present evidence.
Wikstrand J; Berglund G; Tuomilehto J
Circulation; 1991 Dec; 84(6 Suppl):VI93-100. PubMed ID: 1683615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
